Back to Sectors

ECOR

electroCore, Inc.
6 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

BEARISH | 70% | 5/6/2026 | earnings missBULLISH | 80% | 5/6/2026 | margin expansionNEUTRAL | 50% | 5/6/2026 | capital raiseBEARISH | 60% | 5/6/2026 | regulatory actionNEUTRAL | 40% | 5/6/2026 | management changeBEARISH | 70% | 5/6/2026 | earnings missBULLISH | 80% | 5/6/2026 | margin expansionNEUTRAL | 50% | 5/6/2026 | capital raiseBEARISH | 60% | 5/6/2026 | regulatory actionNEUTRAL | 40% | 5/6/2026 | management changeBEARISH | 70% | 5/6/2026 | earnings missBULLISH | 80% | 5/6/2026 | margin expansionNEUTRAL | 50% | 5/6/2026 | capital raiseBEARISH | 60% | 5/6/2026 | regulatory actionNEUTRAL | 40% | 5/6/2026 | management changeBEARISH | 70% | 5/6/2026 | earnings missBULLISH | 80% | 5/6/2026 | margin expansionNEUTRAL | 50% | 5/6/2026 | capital raiseBEARISH | 60% | 5/6/2026 | regulatory actionNEUTRAL | 40% | 5/6/2026 | management changeBEARISH | 70% | 5/6/2026 | earnings missBULLISH | 80% | 5/6/2026 | margin expansionNEUTRAL | 50% | 5/6/2026 | capital raiseBEARISH | 60% | 5/6/2026 | regulatory actionNEUTRAL | 40% | 5/6/2026 | management changeBEARISH | 70% | 5/6/2026 | earnings missBULLISH | 80% | 5/6/2026 | margin expansionNEUTRAL | 50% | 5/6/2026 | capital raiseBEARISH | 60% | 5/6/2026 | regulatory actionNEUTRAL | 40% | 5/6/2026 | management changeMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 6

Net loss widened to $5.3 million as operating expenses outpaced revenue growth.

earnings miss
70%
bullishMay 6

Gross margins expanded to 87% due to favorable product mix and scale.

margin expansion
80%
neutralMay 6

Reliance on ATM facility and shelf registration to fund operations amid liquidity crisis.

capital raise
50%
bearishMay 6

Unannounced 'for-cause' FDA inspection of New Jersey facility.

regulatory action
60%
neutralMay 6

Transition following the retirement of CEO Daniel Goldberger.

management change
40%
bearishMay 6

Net loss widened to $5.3 million as operating expenses outpaced revenue growth.

earnings miss
70%
bullishMay 6

Gross margins expanded to 87% due to favorable product mix and scale.

margin expansion
80%
neutralMay 6

Reliance on ATM facility and shelf registration to fund operations amid liquidity crisis.

capital raise
50%
bearishMay 6

Unannounced 'for-cause' FDA inspection of New Jersey facility.

regulatory action
60%
neutralMay 6

Transition following the retirement of CEO Daniel Goldberger.

management change
40%
bearishMay 6

Net loss widened to $5.3 million as operating expenses outpaced revenue growth.

earnings miss
70%
bullishMay 6

Gross margins expanded to 87% due to favorable product mix and scale.

margin expansion
80%
neutralMay 6

Reliance on ATM facility and shelf registration to fund operations amid liquidity crisis.

capital raise
50%
bearishMay 6

Unannounced 'for-cause' FDA inspection of New Jersey facility.

regulatory action
60%
neutralMay 6

Transition following the retirement of CEO Daniel Goldberger.

management change
40%
bearishMay 6

Net loss widened to $5.3 million as operating expenses outpaced revenue growth.

earnings miss
70%
bullishMay 6

Gross margins expanded to 87% due to favorable product mix and scale.

margin expansion
80%
neutralMay 6

Reliance on ATM facility and shelf registration to fund operations amid liquidity crisis.

capital raise
50%
bearishMay 6

Unannounced 'for-cause' FDA inspection of New Jersey facility.

regulatory action
60%
neutralMay 6

Transition following the retirement of CEO Daniel Goldberger.

management change
40%
bearishMay 6

Net loss widened to $5.3 million as operating expenses outpaced revenue growth.

earnings miss
70%
bullishMay 6

Gross margins expanded to 87% due to favorable product mix and scale.

margin expansion
80%
neutralMay 6

Reliance on ATM facility and shelf registration to fund operations amid liquidity crisis.

capital raise
50%
bearishMay 6

Unannounced 'for-cause' FDA inspection of New Jersey facility.

regulatory action
60%
neutralMay 6

Transition following the retirement of CEO Daniel Goldberger.

management change
40%
bearishMay 6

Net loss widened to $5.3 million as operating expenses outpaced revenue growth.

earnings miss
70%
bullishMay 6

Gross margins expanded to 87% due to favorable product mix and scale.

margin expansion
80%
neutralMay 6

Reliance on ATM facility and shelf registration to fund operations amid liquidity crisis.

capital raise
50%
bearishMay 6

Unannounced 'for-cause' FDA inspection of New Jersey facility.

regulatory action
60%
neutralMay 6

Transition following the retirement of CEO Daniel Goldberger.

management change
40%

Filing History

10-QMay 6, 2026

The Q1 2026 filing presents a stark contrast between accelerating commercial momentum and deteriorating financial stability. On one hand, the 43% revenue jump and 87% gross margins suggest a product-market fit that is scaling rapidly, particularly within government channels. The integration of NURO has successfully broadened the company's therapeutic reach, and the expansion into wellness markets provides a potential hedge against prescription volatility. However, these operational wins are overshadowed by a looming liquidity crisis and systemic risks. The combination of a 'going concern' qualification, a heavy debt load from the Avenue term loan, and an unannounced FDA inspection creates a high-risk environment for investors. The overall impact of the filing is a narrative of a company that has a viable product and growing demand but lacks the financial discipline or capital structure to ensure its own survival without further significant dilution or external funding.